Prosecution Insights
Last updated: April 19, 2026
Application No. 18/264,918

THERAPEUTIC COMPOSITION BASED ON DHODH-INHIBITING NEUROLAENA LEAVES FOR THE TREATMENT OF RNA VIRUS INFECTIONS

Non-Final OA §112
Filed
Aug 09, 2023
Examiner
MI, QIUWEN
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Phytobokaz
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
1065 granted / 1565 resolved
+8.1% vs TC avg
Strong +50% interview lift
Without
With
+50.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
41 currently pending
Career history
1606
Total Applications
across all art units

Statute-Specific Performance

§101
10.9%
-29.1% vs TC avg
§103
38.4%
-1.6% vs TC avg
§102
25.8%
-14.2% vs TC avg
§112
19.1%
-20.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1565 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election/Restrictions Claims 1-8 are pending. Applicant’s election without traverse of Group II, claims 3-6, in the reply filed on 10/16/25 is acknowledged. Claims 1, 2, 7, and 8 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 10/16/25. Claims 3-6 are examined on the merits. Claim Rejections –35 USC § 112, 2nd The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3-6 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 3 iv), at lines 1-2 recites “diluting said liquid mother tincture to ¼ by adding and aqueous solution”. The recitation is confusing, diluting is supposed to increase the volume of liquid mother tincture, instead of decrease the volume, does Applicant mean to recite “diluting said liquid mother tincture to 4 times?” Regarding claims 4 (at last line) and 6 (at second line from the bottom), the phrase "preferably" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Therefore, the metes and bounds of claims are rendered vague and indefinite. The lack of clarity renders the claims very confusing and ambiguous since the resulting claims do not clearly set forth the metes and bounds of the patent protection desired. All other cited claims depend directly or indirectly from rejected claims and are, therefore, also, rejected under U.S.C. 112, second paragraph for the reasons set forth above. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QIUWEN MI whose telephone number is (571)272-5984. The examiner can normally be reached on Monday-Friday 9:00 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Qiuwen Mi/ Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Aug 09, 2023
Application Filed
Mar 14, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599632
THERAPEUTIC AGENT FOR NERVE DISORDERS
2y 5m to grant Granted Apr 14, 2026
Patent 12599552
COSMETIC COMPOSITION CONTAINING EXTRACT OF CYPERUS ROTUNDUS FOR ANTI-INFLAMMATION, SKIN SOOTHING, IRRITATION RELIEF, AND SKIN BARRIER ENHANCEMENT
2y 5m to grant Granted Apr 14, 2026
Patent 12594233
FAT AND/OR WAX ACTIVATED BY MEANS OF THE WATER-INSOLUBLE FRACTION OF CARICA PAPAYA SAP
2y 5m to grant Granted Apr 07, 2026
Patent 12594316
PLANT COMPOSITION, TRADITIONAL CHINESE MEDICINE COMPOSITION AND USE THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12589121
METHOD FOR OBTAINING OCCLUSIVE BIOLOGICAL DRESSING, OCCLUSIVE BIOLOGICAL DRESSING, USE THEREOF AND KIT
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+50.0%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 1565 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month